Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
复制标题
DOI：
10.1111/j.1749-6632.2011.05972.x
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Hazuda, Daria J.
中科院分区：
文献类型：
--
作者：
Nguyen, Bach-Yen T.;Isaacs, Robin D.;Hazuda, Daria J.
雷特格韦是第一个被批准用于治疗HIV-1感染的整合酶链转移抑制剂。作为这类新型抗逆转录病毒疗法的第一种药物，雷特格韦已在初治和重度预治疗的艾滋病毒感染患者中证明了安全性和有效性，这些患者用多重耐药病毒治疗失败。雷特格韦具有良好的药物相互作用特征，允许广泛的人口统计学多样化的患者人群给药，并与许多其他治疗药物（包括抗逆转录病毒药物和支持药物）联合给药，而无需限制或剂量调整。三项III期研究（方案021（STARTMRK）用于初治患者，方案018（BENCHMRK-1）和方案019（BENCHMRK-2）用于有治疗经验的患者）的96周随访数据证明，雷特格韦在初治和有治疗经验的患者中均具有强效和持久的抗逆转录病毒和免疫学作用以及良好的长期安全性特征。雷特格韦代表了对目前治疗HIV感染的药物的重要补充。
Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment-naive as well as heavily pretreated HIV-infected patients failing therapy with multidrug-resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow-up in three phase III studies, protocol 021 (STARTMRK) in treatment-naive patients, and protocols 018 (BENCHMRK-1) and 019 (BENCHMRK-2) in treatment-experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long-term safety profile of raltegravir in both treatment-naive and treatment-experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection.